Monday, January 17, 2000
The battle for the now-hot antibody market is being fought
on two fronts: among competing transgenic mouse technologies for human antibody
production, and between those mice and older technologies including phage display
and antibody humanization.
For the increasingly popular human antibody companies, the
challenge is to manage an over-abundance of riches, both in terms of targets
and partners, while adding technologies that make the mice even more useful.
For humanized antibody developers, the challenge is getting investors to remember
that the companies have rich pipelines of products at all stages of development,
and that there appears to be no clinical difference between the two types of
Of mice and MEDX
Medarex Inc. is looking to strengthen its human antibody technology
portfolio. By in-licensing Kirin Brewery Co. Ltd.'s transchromosomic-mice (TC
mice), MEDX hopes not only to gain a larger share of human antibody production,
but also to more completely displace other antibody approaches.